PAYS
Paysign Inc
NASDAQ NMS - GLOBAL MARKET· Financial Services· US· IPO 2001-07-19
$12.53
+0.13 (+1.09%)
last quote
Want the full multi-source brief on PAYS?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$12.53
High
$12.66
Low
$12.22
Previous close
$12.39
Fundamentals
Market cap
$739.94M
P/E (TTM)
46.91x
P/S (TTM)
7.35x
P/B
5.85x
Gross margin
61.00%
Operating margin
17.01%
Net margin
15.67%
Rev growth (YoY)
46.84%
EPS growth (YoY)
111.13%
ROE
30.13%
52W high
$14.43
52W low
$3.08
Beta
0.94x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-10in 67 days
Q3 2026EPS est $0.09Rev est $29.6M
Recent SEC filings
CIK 1496443filing-language history →
Recent news
2026-08-27 → 2026-09-03
SeekingAlpha · 1d
Top Stocks Averaging 100% Forward EPS Growth To Combat AI Capex Fatigue
Discover three Quant Strong Buy stocks with strong forward EPS growth that offer investors opportunities beyond the AI capex boom. Click here to see the top 3 stocks.
ChartMill · 1d
Paysign Inc (NASDAQ:PAYS) Shows High-Growth Leadership and Strong Momentum
Paysign (PAYS) fits CAN SLIM with 450% EPS growth, 48% sales growth, strong momentum, and zero debt, but high valuation and volatility warrant caution.
SeekingAlpha · 3d
Paysign: Growth In Both Segments, But Guidance Implies Lower H2 Earnings
Paysign grew Q2 revenue 48.1% YoY to $28.3 million, raised 2026 guidance twice, and got plasma growing 21.4% after a flat 2025. Learn more about PAYS stock here.
SeekingAlpha · 6d
Paysign: The Bull Case Is No Longer About Prepaid Cards
Paysign, Inc. is rated a Hold and is transforming from a prepaid card processor to higher-margin healthcare payments. Read more on PAYS stock here.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial